October 2025 OrbusNeich announced that cumulative global shipments and implantations of its coronary intervention devices had exceeded 10 million units. The milestone reflects the company's continued expansion of its interventional portfolio, including microcatheters, guide extension catheters, and balloon catheter technologies across international markets.
August 2025 Researchers from the ETH Zurich and collaborating institutions introduced a flow-driven magnetic microcatheter for superselective arterial embolization. The next-generation technology enables navigation through highly tortuous and ultra-small blood vessels, advancing minimally invasive neurovascular interventions.
June 2025 OrbusNeich acquired Taiwan Rich Medical, strengthening its direct sales network in Taiwan and expanding its commercial presence for coronary intervention products, including its Teleport® microcatheter portfolio. The acquisition supports broader regional market access and customer engagement.
May 2025 Meril Life Sciences expanded its vascular intervention portfolio with the launch of MyClip, a transcatheter edge-to-edge repair (TEER) device for mitral valve repair. The launch strengthens the company's minimally invasive cardiovascular portfolio, complementing its interventional catheter technologies.